ArticleToxicology letters2016
Mouse tissue distribution and persistence of the food-born fusariotoxins Enniatin B and Beauvericin.
Article in Toxicology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 63 citations in OpenAlex.
- Current status of human biomonitoring of beauvericin and enniatins.Archives of toxicology · 2026Review
- Distinguishing cytotoxicity-associated and direct immunomodulatory effects of enniatins and beauvericin in human immune and intestinal cells.Mycotoxin research · 2026Article
- Enniatins and Beauvericin as Emerging Mycotoxins in the Context of Climate Change in Europe.Toxins · 2026Review
- Article
- Occurrence of mycotoxins in fish feed and its consequences for aquaculture with special regard to the role of insect products.Mycotoxin research · 2026Review
- The role of mycotoxins in lipid metabolism and homeostasis: a systematic review.Frontiers in toxicology · 2026Review
- Hazard characterization of the mycotoxins enniatins and beauvericin to identify data gaps and improve risk assessment for human health.Archives of toxicology · 2025Review
- Anti-tumor activity of beauvericin: focus on intracellular signaling pathways.Mycotoxin research · 2024Review
- ABC transporter inhibition by beauvericin partially overcomes drug resistance inAntimicrobial agents and chemotherapy · 2024Article
- Review
- Evaluation of distribution of emerging mycotoxins in human tissues: applications of dispersive liquid-liquid microextraction and liquid chromatography-mass spectrometry.Analytical and bioanalytical chemistry · 2024Article
- Impact of Enniatin B and Beauvericin on Lysosomal Cathepsin B Secretion and Apoptosis Induction.International journal of molecular sciences · 2023Article
- In Vitro Effects of Enniatin A on Steroidogenesis and Proliferation of Bovine Granulosa Cells.Toxins · 2022Article
- Article
- Role of Nrf2 Nucleus Translocation in Beauvericin-Induced Cell Damage in Rat Hepatocytes.Toxins · 2022Article
- Evaluation of prophylactic efficacy of cinnamaldehyde in murine model against Paradendryphiella arenariae mycotoxin tenuazonic acid-induced oxidative stress and organ toxicity.Scientific reports · 2021Article
- Cytoprotective Effects of Fish Protein Hydrolysates against HAntioxidants (Basel, Switzerland) · 2021Article
- Beauvericin alters the expression of genes coding for key proteins of the mitochondrial chain in ovine cumulus-oocyte complexes.Mycotoxin research · 2021Article
- Review
- Mycotoxins: Biotransformation and Bioavailability Assessment Using Caco-2 Cell Monolayer.Toxins · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
Abstract
The fusariotoxins Enniatin B (Enn B) and Beauvericin (Bea) have recently aroused interest as food contaminants and as potential anticancer drugs. However, limited data are available about their toxic profile. Aim of this study was to investigate their pharmacological behavior in vivo and their persistence in mice. Therefore, liquid chromatography tandem mass spectrometry (LC-MS/MS) was used to analyze the distribution of Enn B and Bea in selected tissue samples and biological fluids originating from mice treated intraperitoneally with these cyclohexadepsipeptides. Overall, no toxicological signs during life time or pathological changes were observed. Moreover, both fusariotoxins were found in all tissues and serum but not in urine. Highest amounts were measured in liver and fat demonstrating the moleculeś tendency to bioaccumulate in lipophilic tissues. While for Bea no metabolites could be detected, for Enn B three phase I metabolites (dioxygenated-Enn B, mono- and di-demethylated-Enn B) were found in liver and colon, with dioxygenated-Enn B being most prominent. Consequently, contribution of hepatic as well as intestinal metabolism seems to be involved in the overall metabolism of Enn B. Thus, despite their structural similarity, the metabolism of Enn B and Bea shows distinct discrepancies which might affect long-term effects and tolerability in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.